|
1
|
Casares N, Pequignot MO, Tesniere A,
Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs
S, Obeid M, et al: Caspase-dependent immunogenicity of
doxorubicin-induced tumor cell death. J Exp Med. 202:1691–1701.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Galluzzi L, Senovilla L, Zitvogel L and
Kroemer G: The secret ally: Immunostimulation by anticancer drugs.
Nat Rev Drug Discov. 11:215–233. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hernandez-Alcoceba R and Berraondo P:
Immunochemotherapy against colon cancer by gene transfer of
interleukin-12 in combination with oxaliplatin. Oncoimmunology.
1:97–99. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zitvogel L and Kroemer G: Anticancer
immunochemotherapy using adjuvants with direct cytotoxic effects. J
Clin Invest. 119:2127–2130. 2009.PubMed/NCBI
|
|
5
|
Lake RA and Robinson BW: Immunotherapy and
chemotherapy-a practical partnership. Nat Rev Cancer. 5:397–405.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nowak AK, Robinson BW and Lake RA:
Gemcitabine exerts a selective effect on the humoral immune
response: Implications for combination chemo-immunotherapy. Cancer
Res. 62:2353–2358. 2002.PubMed/NCBI
|
|
7
|
Green DR, Ferguson T, Zitvogel L and
Kroemer G: Immunogenic and tolerogenic cell death. Nat Rev Immunol.
9:353–363. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Galluzzi L, Vitale I, Abrams JM, Alnemri
ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry
WS, Fulda S, et al: Molecular definitions of cell death
subroutines: Recommendations of the nomenclature committee on cell
death 2012. Cell Death Differ. 19:107–120. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zitvogel L, Galluzzi L, Smyth MJ and
Kroemer G: Mechanism of action of conventional and targeted
anticancer therapies: Reinstating immunosurveillance. Immunity.
39:74–88. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mosser DM and Edwards JP: Exploring the
full spectrum of macrophage activation. Nat Rev Immunol. 8:958–969.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Alizadeh D, Trad M, Hanke NT, Larmonier
CB, Janikashvili N, Bonnotte B, Katsanis E and Larmonier N:
Doxorubicin eliminates myeloid-derived suppressor cells and
enhances the efficacy of adoptive T-cell transfer in breast cancer.
Cancer Res. 74:104–118. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lutsiak ME, Semnani RT, De Pascalis R,
Kashmiri SV, Schlom J and Sabzevari H: Inhibition of CD4(+)25+ T
regulatory cell function implicated in enhanced immune response by
low-dose cyclophosphamide. Blood. 105:2862–2868. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Madajewicz S, Waterhouse DM, Ritch PS,
Khan MQ, Higby DJ, Leichman CG, Malik SK, Hentschel P, Gill JF,
Zhao L and Nicol SJ: Multicenter, randomized phase II trial of
bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG)
versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin
(FOLFOX4) as first-line therapy for patients with advanced
colorectal cancer. Invest New Drugs. 30:772–778. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang L, Dermawan K, Jin M, Liu R, Zheng
H, Xu L, Zhang Y, Cai Y, Chu Y and Xiong S: Differential impairment
of regulatory T cells rather than effector T cells by
paclitaxel-based chemotherapy. Clin Immunol. 129:219–229. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vincent J, Mignot G, Chalmin F, Ladoire S,
Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C and
Ghiringhelli F: 5-Fluorouracil selectively kills tumor-associated
myeloid-derived suppressor cells resulting in enhanced T
cell-dependent antitumor immunity. Cancer Res. 70:3052–3061. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kodumudi KN, Woan K, Gilvary DL, Sahakian
E, Wei S and Djeu JY: A novel chemoimmunomodulating property of
docetaxel: suppression of myeloid-derived suppressor cells in tumor
bearers. Clin Cancer Res. 16:4583–4594. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suzuki E, Kapoor V, Jassar AS, Kaiser LR
and Albelda SM: Gemcitabine selectively eliminates splenic
Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and
enhances antitumor immune activity. Clin Cancer Res. 11:6713–6721.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ding ZC, Lu X, Yu M, Lemos H, Huang L,
Chandler P, Liu K, Walters M, Krasinski A, Mack M, et al:
Immunosuppressive myeloid cells induced by chemotherapy attenuate
antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. Cancer
Res. 74:3441–3453. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kanterman J, Sade-Feldman M, Biton M,
Ish-Shalom E, Lasry A, Goldshtein A, Hubert A and Baniyash M:
Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on
myeloid-derived suppressor cells and colorectal cancer outcomes.
Cancer Res. 74:6022–6035. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dijkgraaf EM, Heusinkveld M, Tummers B,
Vogelpoel LT, Goedemans R, Jha V, Nortier JW, Welters MJ, Kroep JR
and van der Burg SH: Chemotherapy alters monocyte differentiation
to favor generation of cancer-supporting M2 macrophages in the
tumor microenvironment. Cancer Res. 73:2480–2492. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Graham J, Mushin M and Kirkpatrick P:
Oxaliplatin. Nat Rev Drug Discov. 3:11–12. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tesniere A, Schlemmer F, Boige V, Kepp O,
Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault
L, et al: Immunogenic death of colon cancer cells treated with
oxaliplatin. Oncogene. 29:482–491. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gervais MK, Dubé P, McConnell Y, Drolet P,
Mitchell A and Sideris L: Cytoreductive surgery plus hyperthermic
intraperitoneal chemotherapy with oxaliplatin for peritoneal
carcinomatosis arising from colorectal cancer. J Surg Oncol.
108:438–443. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Elias D, Gilly F, Boutitie F, Quenet F,
Bereder JM, Mansvelt B, Lorimier G, Dubè P and Glehen O: Peritoneal
colorectal carcinomatosis treated with surgery and perioperative
intraperitoneal chemotherapy: Retrospective analysis of 523
patients from a multicentric French study. J Clin Oncol. 28:63–68.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Buhtoiarov IN, Sondel PM, Wigginton JM,
Buhtoiarova TN, Yanke EM, Mahvi DA and Rakhmilevich AL: Anti-tumour
synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN
immunotherapy through repolarization of tumour-associated
macrophages. Immunology. 132:226–239. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hori S, Nomura T and Sakaguchi S: Control
of regulatory T cell development by the transcription factor Foxp3.
Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pucci F, Venneri MA, Biziato D, Nonis A,
Moi D, Sica A, Di Serio C, Naldini L and De Palma M: A
distinguishing gene signature shared by tumor-infiltrating
Tie2-expressing monocytes, blood ‘resident’ monocytes, and
embryonic macrophages suggests common functions and developmental
relationships. Blood. 114:901–914. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gabrilovich DI and Nagaraj S:
Myeloid-derived suppressor cells as regulators of the immune
system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez
AC, Benninger K, Khan M, Kuppusamy P, Guenterberg K, Kondadasula
SV, Chaudhury AR, La Perle KM, et al: Myeloid-derived suppressor
cell inhibition of the IFN response in tumor-bearing mice. Cancer
Res. 71:5101–5110. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wesolowski R, Markowitz J and Carson WE
III: Myeloid derived suppressor cells-a new therapeutic target in
the treatment of cancer. J Immunother Cancer. 1:102013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Alizadeh D and Larmonier N:
Chemotherapeutic targeting of cancer-induced immunosuppressive
cells. Cancer Res. 74:2663–2668. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zitvogel L, Tesniere A and Kroemer G:
Cancer despite immunosurveillance: Immunoselection and
immunosubversion. Nat Rev Immunol. 6:715–727. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Colombo MP and Piconese S:
Regulatory-T-cell inhibition versus depletion: The right choice in
cancer immunotherapy. Nat Rev Cancer. 7:880–887. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Restifo NP, Dudley ME and Rosenberg SA:
Adoptive immunotherapy for cancer: Harnessing the T cell response.
Nat Rev Immunol. 12:269–281. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dudley ME, Wunderlich JR, Robbins PF, Yang
JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP,
Hubicki AM, et al: Cancer regression and autoimmunity in patients
after clonal repopulation with antitumor lymphocytes. Science.
298:850–854. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wrzesinski C, Paulos CM, Gattinoni L,
Palmer DC, Kaiser A, Yu Z, Rosenberg SA and Restifo NP:
Hematopoietic stem cells promote the expansion and function of
adoptively transferred antitumor CD8 T cells. J Clin Invest.
117:492–501. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gabrilovich DI, Ostrand-Rosenberg S and
Bronte V: Coordinated regulation of myeloid cells by tumours. Nat
Rev Immunol. 12:253–268. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun HL, Zhou X, Xue YF, Wang K, Shen YF,
Mao JJ, Guo HF and Miao ZN: Increased frequency and clinical
significance of myeloid-derived suppressor cells in human
colorectal carcinoma. World J Gastroenterol. 18:3303–3309.
2012.PubMed/NCBI
|
|
39
|
Kanterman J, Sade-Feldman M and Baniyash
M: New insights into chronic inflammation-induced
immunosuppression. Semin Cancer Biol. 22:307–318. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Michels T, Shurin GV, Naiditch H, Sevko A,
Umansky V and Shurin MR: Paclitaxel promotes differentiation of
myeloid-derived suppressor cells into dendritic cells in vitro in a
TLR4-independent manner. J Immunotoxicol. 9:292–300. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mattarollo SR, Loi S, Duret H, Ma Y,
Zitvogel L and Smyth MJ: Pivotal role of innate and adaptive
immunity in anthracycline chemotherapy of established tumors.
Cancer Res. 71:4809–4820. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Heusinkveld M and van der Burg SH:
Identification and manipulation of tumor associated macrophages in
human cancers. J Transl Med. 9:2162011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sica A and Mantovani A: Macrophage
plasticity and polarization: In vivo veritas. J Clin Invest.
122:787–795. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP,
Wu C and Zheng L: Activated monocytes in peritumoral stroma of
hepatocellular carcinoma foster immune privilege and disease
progression through PD-L1. J Exp Med. 206:1327–1337. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Galdiero MR, Garlanda C, Jaillon S, Marone
G and Mantovani A: Tumor associated macrophages and neutrophils in
tumor progression. J Cell Physiol. 228:1404–1412. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lievense LA, Bezemer K, Aerts JG and
Hegmans JP: Tumor-associated macrophages in thoracic malignancies.
Lung Cancer. 80:256–262. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang H, Wang X, Shen Z, Xu J, Qin J and
Sun Y: Infiltration of diametrically polarized macrophages predicts
overall survival of patients with gastric cancer after surgical
resection. Gastric Cancer. 18:740–750. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A
and Di W: A high M1/M2 ratio of tumor-associated macrophages is
associated with extended survival in ovarian cancer patients. J
Ovarian Res. 7:192014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sica A, Schioppa T, Mantovani A and
Allavena P: Tumour-associated macrophages are a distinct M2
polarised population promoting tumour progression: Potential
targets of anti-cancer therapy. Eur J Cancer. 42:717–727. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tang X, Mo C, Wang Y, Wei D and Xiao H:
Anti-tumour strategies aiming to target tumour-associated
macrophages. Immunology. 138:93–104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nywening TM, Wang-Gillam A, Sanford DE,
Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA,
Yano M, et al: Targeting tumour-associated macrophages with CCR2
inhibition in combination with FOLFIRINOX in patients with
borderline resectable and locally advanced pancreatic cancer: A
single-centre, open-label, dose-finding, non-randomised, phase 1b
trial. Lancet Oncol. 17:651–662. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang X, Deavers M, Patenia R, Bassett RL
Jr, Mueller P, Ma Q, Wang E and Freedman RS: Monocyte/macrophage
and T-cell infiltrates in peritoneum of patients with ovarian
cancer or benign pelvic disease. J Transl Med. 4:302006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Robinson-Smith TM, Isaacsohn I, Mercer CA,
Zhou M, Van Rooijen N, Husseinzadeh N, McFarland-Mancini MM and
Drew AF: Macrophages mediate inflammation-enhanced metastasis of
ovarian tumors in mice. Cancer Res. 67:5708–5716. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ko SY, Ladanyi A, Lengyel E and Naora H:
Expression of the homeobox gene HOXA9 in ovarian cancer induces
peritoneal macrophages to acquire an M2 tumor-promoting phenotype.
Am J Pathol. 184:271–281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bak SP, Walters JJ, Takeya M,
Conejo-Garcia JR and Berwin BL: Scavenger receptor-A-targeted
leukocyte depletion inhibits peritoneal ovarian tumor progression.
Cancer Res. 67:4783–4789. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Shevach EM: Mechanisms of foxp3+ T
regulatory cell-mediated suppression. Immunity. 30:636–645. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ghiringhelli F, Larmonier N, Schmitt E,
Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E,
Bonnotte B and Martin F: CD4+CD25+ regulatory T cells suppress
tumor immunity but are sensitive to cyclophosphamide which allows
immunotherapy of established tumors to be curative. Eur J Immunol.
34:336–344. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Banissi C, Ghiringhelli F, Chen L and
Carpentier AF: Treg depletion with a low-dose metronomic
temozolomide regimen in a rat glioma model. Cancer Immunol
Immunother. 58:1627–1634. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Gonzalez-Aparicio M, Alzuguren P, Mauleon
I, Medina-Echeverz J, Hervas-Stubbs S, Mancheno U, Berraondo P,
Crettaz J, Gonzalez-Aseguinolaza G, Prieto J and Hernandez-Alcoceba
R: Oxaliplatin in combination with liver-specific expression of
interleukin 12 reduces the immunosuppressive microenvironment of
tumours and eradicates metastatic colorectal cancer in mice. Gut.
60:341–349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Gou HF, Huang J, Shi HS, Chen XC and Wang
YS: Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits
colon cancer metastasis in mice. PLoS One. 9:e857892014. View Article : Google Scholar : PubMed/NCBI
|
